Yuho Najima
Hematology — Tokyo Metropolitan Komagome Hospital, Japan
Yuho Najima
LeadR Profile
Hematology
Subspecialties: Transplantation - Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 256
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical impact of infused CD3-positive cell dose in unrelated peripheral blood stem cell transplantation. cells, mortality, blood, microscopy, electron, scanning transmission, peripheral blood stem cell transplantation, stem cells, peripheral blood stem cells, transplants, cell transplantation, stem cell transplantation, transplantation | Int J Hematol | 2026 | 0 |
| Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes. myelodysplastic syndromes, blood, leukemia, leukemia, myeloid, acute, leukemia, myeloid, transplants, therapeutics, transplantation | Int J Hematol | 2026 | 0 |
| Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21). lymphocytes, gemtuzumab, leukemia, leukemia, myeloid, acute, maintenance, immune system diseases, leukemia, myeloid, transplants, therapeutics | Front Immunol | 2026 | 0 |
| Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin. precursor cell lymphoblastic leukemia-lymphoma, leukemia, leukemia, myeloid, acute, immunotherapy, inotuzumab ozogamicin, immune system diseases, leukemia, myeloid, therapeutics, clone cells, mutation | Front Immunol | 2026 | 0 |
| Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML. neoplasms, leukemia, myeloid, acute, therapeutics, mutation, drug resistance | Cancer Sci | 2026 | 0 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map